Skip to main content
. 2020 Feb 27;53:102686. doi: 10.1016/j.ebiom.2020.102686

Fig. 5.

Fig. 5

Flow cytometry analysis of CD3-CD7+GZMB+ subsets in HC, LTBI and TB. (a) Gating strategy of CD3-CD7+GZMB+ by flow cytometry. (b) The frequency of CD3-CD7+GZMB+ in HC and TB in the second cohort (HC=81, TB=50). (c) The frequency of CD3-CD7+GZMB+ in HC, LTBI and TB in the third cohort (HC=39, LTBI=27, and TB=37). (d–f) ROC curve for CD3-CD7+GZMB+ to separate TB from HC (d, e) or LTBI (f). AUC=0.93 (d), AUC=0.96 (e), AUC=0.85 (f). AUC, area under curve. (g,h)The frequency of CD3-CD7+GZMB+ is increased after anti-TB treatment in TB patients. (g) follow-up TB patients (n = 11) and (h) TB patients received anti-TB treatment from 1 to 10 months (n = 73). A one-way ANOVA Newman–Keuls multiple comparison test was used to compare the differences among multiple groups. An unpaired t-test was used to analyze the differences between two groups. An paired t-test was used to analyze the differences in the follow-up patients. The data represent the means ± SEM. **P < 0. 001, ***P < 0. 001, ****P < 0. 0001.